Gender, first-degree familiarity, the type of IBD, age at starting BioS, age at diagnosis, disease location, perianal involvement, extraintestinal manifestations, previous surgery, being naïve to anti-TNF-α, and other laboratory data (ESR, Hb, fecal calprotectin) were not associated with achieving remission at week 52. The gene discussed is GSTM1; the disease is inflammatory bowel disease.